Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) is expected to issue its Q4 2026 results before the market opens on Monday, October 5th. Analysts expect Neuphoria Therapeutics to announce earnings of ($1.58) per share for the quarter. Investors may visit the the company’s upcoming Q4 2026 earning report page for the latest details on the call scheduled for Friday, September 18, 2026 at 7:00 AM ET.
Neuphoria Therapeutics Price Performance
Shares of NEUP opened at $3.47 on Friday. The company has a market cap of $18.77 million, a P/E ratio of -0.56 and a beta of 0.75. Neuphoria Therapeutics has a 12 month low of $3.19 and a 12 month high of $21.40. The stock has a fifty day moving average price of $3.78 and a 200 day moving average price of $4.25.
Wall Street Analyst Weigh In
Several brokerages have recently commented on NEUP. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Thursday, August 27th. Wall Street Zen upgraded Neuphoria Therapeutics to a “hold” rating in a report on Saturday, July 25th. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $7.00.
Neuphoria Therapeutics Company Profile
Neuphoria Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for obesity and other metabolic diseases. The company’s research programs are designed to address conditions involving weight management, diabetes and metabolic dysfunction.
Neuphoria’s pipeline includes DA-1726, an investigational dual GLP-1 and glucagon receptor agonist being developed for obesity and related metabolic conditions. The company is also developing DA-1241, an investigational GPR119 agonist intended for metabolic dysfunction-associated steatohepatitis, formerly known as nonalcoholic steatohepatitis, and other metabolic disorders.
Recommended Stories
- Five stocks we like better than Neuphoria Therapeutics
- Carnival and CarMax Pop on Strong Earnings, but Challenges Remain
- 3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note
- 3 AI Winners, 3 Very Different Paths to Higher Margins
- Plexus Is Booming—But Can the Growth Story Last?
Receive News & Ratings for Neuphoria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
